For women managing Type 2 diabetes, a new oral medication is showing promising results that could change how we approach treatment. A recent late-stage trial for a new GLP-1 pill called orforglipron demonstrated significant improvements in blood sugar control and weight loss, potentially offering a more convenient option for many.

This new pill is generating excitement because it appears to outperform an existing oral GLP-1 medication, oral semaglutide (known commercially as Rybelsus). Both medications work by mimicking a natural hormone that helps regulate blood sugar and appetite, but orforglipron seems to deliver stronger effects, according to preliminary data.

Stronger Results for Blood Sugar and Weight with New GLP-1 Pill

In the study, approximately 1,700 adults with Type 2 diabetes, all struggling with blood sugar management, were divided into groups receiving either orforglipron or oral semaglutide. Participants started with an average A1C level of 8.3 percent, indicating poorly controlled diabetes. After one year, those on the higher dose of orforglipron saw their A1C levels drop by an impressive 1.9 percent on average, as reported by drugmaker Eli Lilly.

For comparison, participants taking the higher dose of oral semaglutide experienced an average A1C reduction of 1.5 percent. Beyond blood sugar, orforglipron also led to greater weight loss. Patients on the higher orforglipron dose lost almost 18 pounds, or about 8 percent of their starting weight, while those on the higher semaglutide dose lost 11.5 pounds, roughly 5 percent of their initial weight. “On efficacy alone, orforglipron looks better,” notes Dr. Osama Hamdy, an associate professor at Harvard Medical School and medical director of the Obesity Clinical Program at the Joslin Diabetes Center.

Convenience and Side Effects

One notable advantage of orforglipron is its flexibility regarding meal timing. Unlike some other oral medications, there are no restrictions on eating or drinking when taking orforglipron, making it easier to incorporate into daily routines. Dr. Melanie Jay, a professor at the New York University Grossman School of Medicine, highlights this ease of use, especially for those managing multiple medications.

Dr. Marilyn Tan, chief of the endocrine clinic at Stanford Health Care, adds that “adhering to a specific schedule of spacing out various medications can be cumbersome.” This simpler regimen could lead to better adherence for many patients. As with most GLP-1 drugs, common side effects included gastrointestinal issues like nausea, diarrhea, and indigestion. While these were present with both pills, slightly more patients discontinued orforglipron due to side effects compared to oral semaglutide in this trial.

How GLP-1 Medications Work

GLP-1 drugs function by increasing the release of insulin in response to meals, which helps lower blood sugar. They also reduce levels of glucagon, a hormone that can raise blood sugar. This dual action makes them highly effective in managing Type 2 diabetes. Dr. Beverly Tchang, an associate professor at Weill Cornell Medicine, reassures us that these study results provide “further reassurance that both orforglipron and semaglutide are excellent medications to treat type 2 diabetes.”

This new oral option could offer a significant benefit for women seeking effective and convenient ways to manage their Type 2 diabetes. While more research and regulatory approvals are still needed, the initial findings for orforglipron are certainly encouraging for the future of diabetes care.

Source: Everydayhealth | Image: via everydayhealth.com